Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
seizures/hemorràgia
L'enllaç es desa al porta-retalls
Pàgina 1 des de 17 resultats
1,2,4-triazolo[4,3-b]pyridazine derivatives and their use
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This invention relates to certain 1,2,4-triazolo[4,3-b]pyridazines, to pharmaceutical compositions containing them, to processes for their preparation and to their use in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is
Systems, devices and methods for the treatment of neurological disorders and conditions
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
Systems, devices and methods for the treatment of neurological disorders and conditions
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
Systems, devices and methods for the treatment of neurological disorders and conditions
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This application is also related to the following copending applications: U.S. application Ser. No. 12/898,685, entitled "Extracranial Implantable Devices, Systems and Methods for Treatment of Neuropsychiatric Disorders," filed on even date herewith with U.S. application Ser. No. 12/898,686,
Aryl sulfonamides and sulfamide derivatives and uses thereof
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic
Aryl sulfonamides and sulfamide derivatives and uses thereof
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic
Aryl sulfonamides and sulfamide derivatives and uses thereof
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic
Substituted quinoxaline-2-ones as glutamate receptor antagonists
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both
Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The
Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a or b position by amino acid derivatives. The compounds are active as excitatory amino
Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to a method for identifying agents effective in modulating prokineticin receptor, and more specifically to the treatment of cerebrovascular diseases and seizure disorders.
2. Background
Therapeutic agents
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This is a 371 application of PCT/EP 94/03364 filed on Oct. 12, 1994.
This invention relates to derivatives of 1,2,4-triazolo[1,5-a]pyrimidines, to pharmaceutical compositions containing them, to processes for their preparation and to their use in the treatment and/or prophylaxis of seizures,
Therapeutic use of compounds
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This invention relates to uses of compounds. In particular, it relates to the use of compounds in the treatment or prevention of diseases and biomedical conditions such as, seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent
Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention concerns novel urea and thiourea derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by urea or thiourea derivatives. The
Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds which have affinity for 5-HT.sub.1A receptors and which inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
